Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJacalyn RosenblattSASyed Abbas AliEGEli Gabayan

Discussion

Loading...

Member takes

Overview

Phase 1b trial shows combination treatment results in adverse events but with promising efficacy in relapsed myeloma patients.

Key Points

  • Evaluate the safety and efficacy of elranatamab combined with nirogacestat in relapsed or refractory multiple myeloma.
  • Conducted as a sub-study within the Phase 1b MagnetisMM-4 trial
  • Included patients with multiple myeloma and prior treatment history
  • Utilized a Bayesian logistic regression model for dose optimization
  • Identified dose-limiting toxicities across various dose levels
  • Reported adverse events included diarrhea, neutropenia, and infections
  • Combination yielded response rates ranging from 50.0% to 70.0% across dose levels

Cite This Study

Rosenblatt et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da90https://doi.org/10.1182/blood-2025-4058
View Full Paper
Ask AI
Bookmark
Share